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18F-ﬂuoro-deoxy-glucose positron emission
tomography combined with computed tomography
can reliably rule-out infection and cancer in
patients with anti-neutrophil cytoplasmic
antibody-associated vasculitis suspected
of disease relapse
Evan C. Frary, MD, JDa, Søren Hess, MDa,b,c,
∗
, Oke Gerke, MSc, PhDa,d, Helle Laustrup, MD, PhDc,e
Abstract
Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a group of autoimmune diseases characterized by
systemic inﬂammation in small- to medium-sized blood vessels. Although immunosuppressive therapy has greatly improved the
prognosis for these patients, there are still signiﬁcant comorbidities, such as cancer and infection, associated with AAV. These
comorbidities are often indistinguishable from an underlying AAV disease relapse, and create a clinical conundrum, as these
conditions are normally contraindications for immunosuppressive treatment. Thus, it is important to be able to rule out these
comorbidities before initiation of immunosuppressive treatment. We examined 18F-ﬂuoro-deoxy-glucose positron emission
tomography combined with computed tomography (FDG-PET/CT)’s value in ruling out cancer or infection in patients with AAV.
Data were obtained retrospectively for a clinically based cohort of AAV patients who underwent FDG-PET/CT during 2009 to 2014
owing to a suspicion of cancer, infection, or both cancer and infection indistinguishable from disease relapse. FDG-PET/CT
conclusions were compared to the ﬁnal diagnoses after follow-up analysis (mean 43 months).
A total of 19 patients were included who underwent a total of 26 scans. The results of FDG-PET/CT outcome compared to ﬁnal
diagnosis were: 9 true positives, 3 false positives, 13 true negatives, and 1 false negative. The diagnostic probabilities for FDG-PET/
CT with respect to overall comorbidity (i.e., cancer or infection) were: sensitivity 90% ( 95% conﬁdence interval [CI] 60%–98%),
speciﬁcity 81% ( 95% CI 57%–93%), positive predictive value 75% (95% CI 47%–91%), negative predictive value 93% (95% CI
68%–99%), and accuracy 84% (95% CI 66%–94%).
FDG-PET/CT had a high negative predictive value and ruled out the comorbidities correctly in all but one case of urinary tract
infection, a well-known limitation. Our study showed FGD-PET/CT’s promise as an effective tool for ruling out cancer or infection in
patients with AAV albeit in a limited population.
Abbreviations: AAV = ANCA-associated vasculitis, ANCA = anti-neutrophil cytoplasmic antibody, EGPA = eosinophillic
granulomatosis with polyangitis, FDG = 18F-ﬂuoro-deoxy-glucose, FN = false negative, FP = false positive, GPA = granulomatosis
with polyangitis, MPA = microscopic polyangitis, NPV = negative predictive value, PET/CT = positron emission tomography
combined with computed tomography, PPV = positive predictive value, SUVmax = maximum standard uptake values, TN = true
negative, TP = true positive.
Keywords: ANCA, anti-neutrophil cytoplasmic antibody-associated vasculitis, FDG, PET/CT, vasculitis
Editor: Hongming Zhuang.
The authors have no conﬂicts of interest and received no funding for this study.
Authors’ contributions: EF, SH, and HL participated in the study design as well as data collation and interpretation; EF and OG carried out the statistical analysis of the
data; all authors read and approved the ﬁnal manuscript.
a Department of Nuclear Medicine, Odense University Hospital, Odense C, b Department of Radiology and Nuclear Medicine, Hospital of Southwest Jutland, Esbjerg,
c Department of Clinical Research, Faculty of Health Sciences, University of Southern Denmark, Odense C, d Center of Health Economics Research, University of
Southern Denmark, Odense M, e Department of Rheumatology, Odense University Hospital, Odense C, Denmark.
∗
Correspondence: Søren Hess, MD, Department of Nuclear Medicine, Odense University Hospital Sdr. Boulevard 29, 5000 Odense C, Denmark
(e-mail: soeren.hess@rsyd.dk).
Copyright © 2017 the Author(s). Published by Wolters Kluwer Health, Inc.
This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is
permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the
journal.
Medicine (2017) 96:30(e7613)
Received: 17 May 2017 / Received in ﬁnal form: 3 July 2017 / Accepted: 5 July 2017
http://dx.doi.org/10.1097/MD.0000000000007613
Observational Study Medicine®
OPEN
1
1. Introduction
Anti-neutrophil cytoplasmic antibody (ANCA)-associated vas-
culitides (AAV) comprise a group of autoimmune diseases
affecting small- to medium-sized blood vessels including
granulomatosis with polyangitis (GPA, formerly known as
Wegener granulomatosis), microscopic polyangitis (MPA), and
eosinophillic GPA (EGPA, formerly known as Churg Strauss).[1]
AAV’s pathology is characterized by systemic inﬂammation in
the blood vessel’s walls, which can lead to vascular obstruction
and hemorrhage, ultimately resulting in tissue ischemia and
necrosis.[2] Although relatively rare, with 10 to 20 new cases per
million annually,[3] AAV is potentially life-threatening. Histori-
cally, the prognosis for AAV has been bleak, but the survival rates
have improved drastically during the past few decades increasing
from a meager 20% of patients surviving after 1.5 years to a
current 10-year survival rate of 75%.[4–6] This increase has been
largely attributed to a 2-tiered individually tailored immunosup-
pressive therapy based on the disease’s stage and severity.[5–7]
This immunosuppressive therapy, although effective, presents
a serious clinical dilemma to the treating physician, as 2 of
AAV’s associated comorbidities, cancer and infection, are often
clinically indistinguishable from a disease relapse of the patient’s
underlying vasculitis, that is, they present with similar symptoms
and ﬁndings.[6,8] These comorbidities may even be exacerbated
by immunosuppressive treatment and can actually increase
patient morbidity and mortality.[9] Therefore, there is a clinical
need for an effective diagnostic tool, which can help rule out
cancer and infection foci in these patients before immunosup-
pressive therapy is initiated, but hitherto no methods have been
ﬁrmly established for this clinical challenge.
Positron emission tomography combined with computed
tomography (PET/CT) based on high sensitivity detection of
the radiolabeled glucose analog 18F-ﬂuoro-deoxy-glucose (FDG,
which is known to accumulate in hypermetabolic cells) is already
routinely applied to many cancer types as well as the detection of
infection and inﬂammation.[10–12] The capacity to identify all 3 of
these conditions raises the possibility for FDG-PET/CT’s use in
diagnosis and monitoring of AAV patients. Although the role of
FDG-PET/CT has been explored to some degree in large-vessel
vasculitis,[13,14] the evidence with respect to PET/CT’s applica-
bility to AAV is lacking and only includes a few studies with very
limited patient populations.[15–21]
In this article, we report on FDG-PET/CT’s ability to reliably
rule-out comorbidity in the form of cancer or infection in patients
with AAV with nonspeciﬁc symptoms suggestive of either
comorbidities or disease ﬂares.
2. Materials and methods
2.1. Study population
This study included a retrospective clinical cohort of AAV
patients who underwent FDG-PET/CT scans at Odense Univer-
sity Hospital, Denmark. Patients were included in the study if
they had a diagnosis of AAV,[22] and underwent FDG-PET/CT
between January 1, 2009 and December 31, 2014 owing to a
suspicion of comorbidity (cancer, infection, or both) indistin-
guishable from disease relapse. Owing to the rarity of the disease,
no sample size was deﬁned; we wished to include as many
patients as possible in the given period, which was chosen for
practical reasons: The local PET/CT-database was accessible
from 2009 and onwards, and ending inclusion with 2014 enabled
at least a 2-year follow-up period. Patients were not included if
they were referred with a suspicion of a speciﬁc cancer with no
concomitant suspicion of disease relapse.
The data were collected from the hospital’s electronic patient
records and diagnostic imaging systems, and the patients’
journals were manually reviewed for basic information compris-
ing age and sex as well as AAV diagnosis date, FDG-PET/CT
referral indication, FDG-PET/CT date, imaging ﬁndings, and
histological analysis. Follow-up analysis was performed by
reviewing the patients’ electronic records. Birmingham Vasculitis
Activity Scores (BVAS) were calculated post-hoc.
This study was approved by the local ethics committee
(S-20140097) and the Danish Data Protection Agency.
2.2. FDG-PET/CT-protocol
All FDG-PET/CT scans were based on the guidelines from the
European Association of Nuclear Medicine,[23] and performed
according to the department’s standard protocol as previously
described [24]: All examinations were performed on a GE
Discovery PET/CT scanner (GE Healthcare, Milwaukee, WI).
The CT imaging was performed as a low-dose CT scan without
contrast enhancement. Data were reconstructed with a standard
ﬁlter into transaxial slices with a ﬁeld of view of 50cm, matrix
size of 512512 (pixel size 0.98mm), and a slice thickness of
3.75mm. The CT scan was followed immediately by a PET scan
performed using a standard whole-body acquisition protocol
with 6 or 7 bed positions and an acquisition time of 2.5 minutes
per bed position (adjusted to patient size). The scan ﬁeld of view
was 70cm. Attenuation correction was performed from the CT-
scan. The PET data were reconstructed into transaxial slices with
a matrix size of 128128 or 256256 and a slice thickness of
3.75mm using iterative 3D OS-EM (with varying iterations and
subsets), and displayed in coronal, transverse, and sagittal planes.
Corrections for attenuation, randoms, dead time, and normali-
zation were done inside the iterative loop. Analysis of the PET
and fused PET/CT data was done using a GE Advantage
Workstation v. 4.4 or a GE Advantage Server 2.0 (GE
Healthcare). The fused PET/CT scan was described by a nuclear
medicine specialist. At the time of FDG administration, all
patients had fasted for at least 6 hours. PET/CT image acquisition
commenced 60±5minutes, after the administration of a weight-
adjusted dose of 4MBq/kg (110mCi/kg) FDG (minimum 200
MBq (5mCi) and maximum 400MBq [10mCi]). Maximum
standard uptake values (SUVmax) were calculated post-hoc using
Advantage Server 2.0 (GE Healthcare, Milwaukee, WI) by
placing a region of interest (ROI) around all areas of increased
FDG uptake suggestive of malignancy or infection.
2.3. Interpretation
Infection and malignancy were considered simultaneously and
interpreted as overall comorbidity as well as divided into 2
subgroups and interpreted individually.
2.4. Malignancy
All positive FDG-PET/CT ﬁndings were conﬁrmed or rejected by
histological analysis and/or follow-up. An FDG-PET/CT scan
was considered true positive (TP) if there was FDG uptake
suggestive of malignancy (Fig. 1), which was subsequently
conﬁrmed via histological analysis, and false positive (FP) if ruled
out by histological analysis. A true-negative (TN) result was
deﬁned as a scan with no abnormal FDG uptake suggestive of
malignancy in a patient wherein no novel cancer was diagnosed
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in the subsequent follow-up period. A false negative (FN) was
deﬁned as a subsequent novel diagnosis of cancer during follow-
up despite negative FDG-PET/CT.
2.5. Infection
All positive FDG-PET/CT ﬁndings were conﬁrmed or rejected by a
specialist in rheumatology after analysis of all available medical
chart evidence (e.g., clinical observations, paraclinical ﬁndings,
and imaging results from other non-FDG-PET/CT imaging). An
FDG-PET/CT scan was considered TP if there was FDG uptake
suggestive of infection (Fig. 2), which was subsequently conﬁrmed
via the chart data (e.g., positive culture, serology, and/or response
to antibiotic treatment) and FP if ruled out because of discordant
ﬁndings (e.g., negative culture, serology, and/or persistent
symptoms despite antibiotic treatment). A TN result was deﬁned
as a scan without abnormal FDG uptake suggestive of infection
and no subsequent clinical signs or ﬁndings consistent with
infection (e.g., clinical/paraclinical signs indicative of disease
relapse and/or response to immunosuppressive treatment).
Conversely, an FNwas deﬁned as a normal FDG-PET/CTwherein
infection was subsequently conﬁrmed (e.g., positive culture,
serology, and/or response to antibiotic treatment).
2.6. Comorbidity
Infection and malignancy were considered together as overall
comorbidity. TP was deﬁned as a ﬁnding of TP for either cancer
or infection. TN was deﬁned as a ﬁnding of TN for both cancer
and infection. FN was deﬁned as a ﬁnding of FN for cancer or
infection and no simultaneous TP or FP for infection or cancer.
FP was deﬁned as a ﬁnding of FP for cancer or infection and no
simultaneous TP for infection or cancer. These categories were
referral-dependent, for example, if the referral only stated
infection, cancer was not considered and vice versa, but if the
referral stated either suspected infection or cancer, both
diagnoses were considered. In the individual subgroup statistical
analysis, the 6 scans with referral for suspicion of both infection
or cancer were counted as 2 separate exposures, that is, once in
the category of suspected occult cancer and once in the category
of suspected infection, thus resulting in a total of 32 exposures.
2.7. AAV disease activity
A diagnosis of AAV disease relapse was established by a specialist
rheumatologist by analyzing all clinical and paraclinical ﬁndings
(e.g., histological results, increased MPO-ANCA, and/or re-
sponse to immunosuppressive treatment).
2.8. Statistical analysis
FDG-PET/CT’s diagnostic efﬁcacy was analyzed for: sensitivity,
speciﬁcity, positive predictive value (PPV), negative predictive
value (NPV), and accuracy. The corresponding binomial propor-
tion conﬁdence intervals (CIs) were calculated using the Wilson
score interval.[25] Correlation between SUVmax and a TP or
TN result with respect to comorbidity was calculated using the
Wilcoxon-Mann-Whitney test. The analysis dataset was complete,
that is, no data were missing. All statistical analyses were done in
STATA/IC14.0 forWindows (StataCorpLP,College Station,TX).
3. Results
A total of 26 patients were considered for this study, 7 were not
included because of referral for FDG-PET/CT with suspicion of a
speciﬁc cancer and no concomitant suspicion of disease relapse.
This left 19 remaining patients with diagnoses of GPA (n=15) or
MPA (n=4). These 10 male and 9 female patients had a mean age
of 67 years (range 51–78) at the date of scanning, and underwent a
total of 26FDG-PET/CT scans. Sequential scans carried outwithin
Figure 1. Coronal positron emission tomography image (left), computed tomography image (middle), and fused positron emission tomography/computed
tomography image (right) in a patient with known anti-neutrophil cytoplasmic antibody-associated vasculitis referred owing to a suspicion of cancer. There is focally
increased 18F-ﬂuoro-deoxy-glucose uptake in an enlarged left axillary lymph node (red arrows). Subsequent biopsy conﬁrmed a diagnosis of diffuse large B-cell
lymphoma.
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a short timeframeduring the samepatient coursewere counted as 1
scan. Patients were followed up for mean 43months (±3.8months).
3.1. Comorbidity
Overall, there were 12 of 26 positive and 14 of 26 negative FDG-
PET/CT scans. The results of FDG-PET/CT outcome compared
to ﬁnal diagnosis were: 9 TPs, 3 FPs, 13 TNs, and 1 FN. The
overall diagnostic probabilities for FDG-PET/CT with respect to
comorbidity (i.e., cancer or infection) were: sensitivity 90% (95%
CI 60%–98%), speciﬁcity 81% (57%–93%), PPV 75% (95%CI
47%–91%), NPV 93% (95%CI 69%–99%), and accuracy 85%
(95% CI 66%–94%). Individual PET/CT ﬁndings and ﬁnal
diagnoses for this group are displayed in Table 1. The median
Figure 2. Coronal positron emission tomography image (left), computed tomography image (middle), and fused positron emission tomography/computed
tomography image (right) in a patient with known anti-neutrophil cytoplasmic antibody-associated vasculitis referred owing to a suspicion of infection. There is
diffusely increased 18F-ﬂuoro-deoxy-glucose uptake bilaterally consistent with atypical pneumonia and tracheal secretions conﬁrmed pneumocysitis carinii
pneumonia.
Table 1
PET/CT ﬁndings and ﬁnal diagnoses.
Scan Referral indication Symptoms leading to referral BVAS FDG-uptake Final diagnosis Result
1 Cancer vs. relapse Fever 7 Lungs Planocellular carcinoma True positive
2 Cancer vs. relapse Fatigue, blood in urine 0 Lungs, lymph nodes Renal cell carcinoma True positive
3 Cancer vs. relapse Axillary pain and swelling 1 Lymph nodes DLCB lymphoma True positive
4 Cancer vs. relapse Weight loss 2 None No cancer/disease relapse True negative
5 Cancer vs. relapse Weight loss, hypercalcemia, pain 0 None No cancer/disease relapse True negative
6 Cancer vs. relapse Inc. CRP despite steroid treatment 2 None Disease activity True negative
7 Cancer vs. relapse Myelodysplasia 0 None No cancer/disease relapse True negative
8 Cancer vs. relapse Weight loss, fever, dyspnea, leukoscintography 2 None Undetermined cause True negative
9
∗
Cancer vs. relapse Weight loss, Inc. creatinine, hydronephrosis 7 Lungs Lung Fibrosis False positive
10 Infection vs. relapse Inc. CRP, x-ray 4 Lungs Pneumonia True positive
11 Infection vs. relapse Inc. CRP, fever, cough 6 Lungs Pneumonia True positive
12 Infection vs. relapse Inc. CRP, fever 6 Lungs Pneumonia True positive
13 Infection vs. relapse Inc. CRP, fever 12 Lungs, colon, bone Rotavirus, MGUS True positive
14 Infection vs. relapse Inc. CRP, fever 4 Lungs Pneumonia True positive
15 Infection vs. relapse Inc. CRP, fever, dyspnea 9 None Disease activity True negative
16 Infection vs. relapse Inc. CRP, fever, fatigue 10 None Disease activity True negative
17 Infection vs. relapse Fever, fatigue, dizziness, pain 12 None Unknown cause True negative
18 Infection vs. relapse Fever, fatigue, cough 2 None Disease activity True negative
19
∗
Infection vs. relapse Inc. CRP, fever 2 Lung Exudative pleuritis False positive
20 Infection vs. relapse Fever 2 None Urinary tract infection False negative
21 Both vs. relapse Inc. CRP, fever 7 None Lunge emboli True negative
22 Both vs. relapse Inc. CRP, fever, dyspnea, hypoxemia 4 None Lunge emboli True negative
23 Both vs. relapse CT imaging: lung inﬁltrates, lymphadenopathy 10 Lungs, colon Disease activity False positive
24 Both vs. relapse Fever, subjective feeling of illness 6 None Disease activity True negative
25 Both vs. relapse Weight loss, night sweats, decreased appetite 3 None Disease activity True negative
26 Both vs. relapse Inc. CRP, fever, Inc. creatinine 11 Lymph nodes Infection True positive
BVAS=Birmingham Vasculitis Activity Score, CRP=C-reactive protein, DLBC=diffuse large B-cell, FDG= 18F-ﬂuoro-deoxy-glucose, Inc.= increased, MGUS=Monoclonal gammopathy of unknown
signiﬁcance, PET/CT=positron emission tomography/computed tomography.
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BVAS score for all patients was 4 (range: 0–12), and the median
SUVmax for patients with increased FDG uptake suggestive of
cancer or infection was 6.9 (range: 3.7–36.2).
3.2. Individual subgroup analysis
Of the 26 total scans, 9 were undertaken because of suspected
cancer, 11 because of suspected infection, and 6 because of
simultaneous suspicion of either cancer or infection.
In the group referred with suspected cancer, 4 of 9 scans were
positive. Biopsy conﬁrmed novel malignancies in 3 and rejected
malignancy in 1. The remaining 5 of 9 scans were negative, and
no novel cancer was found during follow-up. This resulted in 3
TPs, 1 FPs, 5 TNs, and no FN for this group. Disease relapse of
AAV was conﬁrmed in 2 patients during follow-up.
In the group referred with suspected infection, 6 of 11 were
positive. Infection was subsequently conﬁrmed in 5 and rejected
in 1. Of the remaining 5 of 11 with negative scans, 1 was
determined to in fact have an infection, whereas in the remaining
4, infectionwas ruled out. This resulted in 5 TPs, 1 FP, 4 TNs, and
1 FN for this group. Disease relapse of AAV was conﬁrmed in
4 after follow-up.
In the group referred with a suspicion of cancer or infection,
2 of 6 scans were positive. Infection was subsequently conﬁrmed
in one and both cancer and infection were ruled out in the other.
In the remaining 4 of 6 with negative scans, infection was ruled
out and no novel cancer was found during follow-up. This
resulted in 1 TP, 1 FP, 4 TNs, and no FN for this group. Disease
relapse of AAV was conﬁrmed in 3 patients during follow-up.
The 22 tables for overall comorbidity and each subgroup are
displayed in Table 2. Statistical analyses of FDG-PET/CT’s
diagnostic efﬁcacy for both overall comorbidity as well as the
individual comorbidities are displayed in Table 3. We found no
statistical signiﬁcant correlation between SUVmax values and
comorbidity (z=0.65, P= .52).
4. Discussion
Although a limited number of case reports and case series have
reported on FDG PET/CT’s ability to identify the presence of
active disease in AAV patients,[20,21] we believe this study is the
ﬁrst to evaluate FDG-PET/CT’s role in distinguishing between
AAVdisease activity and comorbidity, that is, cancer or infection.
This is an important but no trivial undertaking, as all of these
clinical entities may induce similar and indistinguishable
symptoms and signs such as fever and elevated inﬂammation
markers. If patients are misclassiﬁed, it may lead to delayed
diagnosis with poorer prognosis, and faulty treatment as the
strategies are fundamentally different; for instance, an immuno-
suppressant for AAV disease activity may seriously worsen
symptoms and harm patients with infection or cancer. One may
even speculate if part of the morbidity or mortality of AAV is
caused by misclassiﬁcation or misdiagnosis of comorbidities.
Although FDG is nonspeciﬁc and as such not able to
differentiate infection, inﬂammation, and cancer per se, the
potential of a high NPV is clear; without focal uptake, the
probability of focal infection or cancer is very low and, thus, any
symptoms and signs are more likely to be attributable to ﬂair of
the underlying inﬂammatory disease. This has also been
addressed in similar settings, for instance, febrile neutropenia
with unknown origin in cancer patients and in patients with fever
of unknown origin wherein FDG-PET/CT has shown consider-
able potential to establish the origin of infection as well as rule out
focal infection with high NPVs.[26–28]
FDG PET/CT correctly ruled out cancer and infection in all but
1 patient. This patient had a case of urinary tract infection, and
although the physiologic urinary excretion of FDG naturally
hampers the use in this setting, urinary tract infections are usually
relatively easy to diagnose via simple alternative tests.[29] The
inability to assess the urinary tract may pose a potential
limitation, however, as cancer of the urinary tract is a known
side effect of the immunosuppressant cyclophosphamide.[9] Even
with this solitary FN, the NPV for overall comorbidity was high
at 93% (95%CI 68%–99%). In the subgroup analysis, NPVwas
even higher for malignancy, 100% (95% CI 70%–100%),
Table 2
FDG-PET/CT vs. comorbidity.
Comorbidity vs. disease relapse (n=26)
Comorbidity positive (+) Comorbidity negative ()
FDG-PET/CT positive (+) 9 TPs 3 FPs
FDG-PET/CT negative () 1 FN 13 TNs
Subgroup analysis
∗
(n=32)
Cancer vs. disease relapse (n=15)
Cancer positive (+) Cancer negative ()
FDG-PET/CT positive (+) 3 TPs 3 FPs
FDG-PET/CT negative () 0 FN 9 TNs
Infection vs. disease relapse (n=17)
Infection positive (+) Infection negative ()
FDG-PET/CT positive (+) 6 TPs 1 FP
FDG-PET/CT negative () 1 FNs 9 TNs
TP= true positive, FDG-PET/CT= F-ﬂuoro-deoxy-glucose-positron emission tomography combined
with computed tomography, FP= false positive, FN= false negative, TN= true negative.
∗
In the individual subgroup statistical analysis, the 6 scans with referral for suspicion of both infection
or cancer were counted as 2 separate exposures, i.e., once in the category of suspected occult cancer
and once in the category of suspected infection, thus resulting in a total of 32 exposures.
Table 3
Diagnostic probabilities of comorbidity.
Comorbidity analysis Subgroup analysis
∗
Comorbidity 95% CI Cancer 95% CI Infection 95% CI
Sensitivity 90% 60–98% 100% 44%–100% 86% 49%–97%
Speciﬁcity 81% 57–93% 75% 47%–91% 90% 60%–98%
PPV 75% 47–91% 50% 19%–81% 86% 49%–97%
NPV 93% 68–99% 100% 70%–100% 90% 60%–98%
Accuracy 84% 66–94% 80% 55%–93% 88% 66%–97%
CI= conﬁdence intervals, NPV=negative predictive value, PPV=positive predictive value.
∗
In the individual subgroup statistical analysis, the 6 scans with referral for suspicion of both infection or cancer were counted as 2 separate exposures, i.e., once in the category of suspected occult cancer and
once in the category of suspected infection, thus resulting in a total of 32.
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whereas the FN reduced the NPV for infection to 90% (95% CI
60%–98%).
Although FDG-PET/CT uncovered novel cancers, the PPV was
moderate with respect to overall comorbidity, that is, 75% (95%
CI 47%–91%). One patient was FP due to extensive lung ﬁbrosis
which mimicked cancer. The subgroup analysis showed a
relatively high PPV in patients with suspected infection, i.e.
86% (95% CI 49%–97%), but a much lower PPV in patients
suspected of cancer, that is 50% (95% CI 19%–81%), in part
owing to the FP ﬁbrosis patient. Another reason was the
retrospective nature of this study, as 1 of the 3 suspected cancer
FPs was owing to a double referral indication, that is, the patient’s
increased FDG uptake was FP with respect to malignancy but
also TPwith respect to infection. The use of more targeted clinical
referral indications would have alleviated this statistical problem.
Thus, our data show overall that whereas the PPV of FDG-
PET/CT is only moderate for cancer or infection, the high NPV
indicates a potentially great beneﬁt of FDG-PET/CT to rule out
occult cancer or infection in these complicated and systemically ill
patients. This is clinically highly relevant, as it allows the rejection
of important differential diagnoses and reduces treatment delay,
that is, administration of immunosuppressants, in AAV patients
suspected of disease relapse.
The lack of statistical signiﬁcance between SUVmax and
comorbidity is not surprising, as the drawbacks of SUVmax are
numerous, and it is well established that SUVmax’s ability to
distinguish between benign or physiologic uptake and infectious
or malignant foci is limited.[30]
The main strengths of our study are that this is the ﬁrst study
ever to report on this particular clinical application of FDG-PET/
CT in AAV patients: a novel method for the clinicians to ensure
no focal infection or malignancy was present before instituting
speciﬁc immunosuppressive treatment for AAV ﬂare. Also of
interest is the nonselected nature of the clinical cohort, which is
representative of the region’s patient population. There were,
however, a number of limitations in our study. The ﬁrst was the
limited number of patients. AAV is rare, however, and with 19
patients, ours is still one of the largest studies to date (the largest
including only 33 patients).[21] Furthermore, the retrospective
design gave rise to inherent drawbacks, for example, the inability
to use single targeted referral indications based on speciﬁc
clinical/paraclinical criteria. However, this was ultimately not
detrimental to the promising ﬁndings as the removal of the double
indication would have actually increased the individual PPV.
FDG-PET/CT’s technological limitations were also a factor to
consider. Owing to FDG-PET/CT’s spatial resolution of 4 to 6
mm, it is not possible to directly display the involvement of small-
medium vessels,[31] but only secondary organ involvement.
Finally, FDG-PET/CT has well-documented areas where it is
difﬁcult to distinguish between physiological and pathological
uptake, for example, the brain, urinary tract, heart, and
bowel.[29]
A few future considerations should be addressed as well. For
example, the effect of steroid treatments on FDG uptake was not
evaluated in our study, although some literature suggests they
have a “masking effect” (i.e., reduced FDG uptake) at least in
large vessel vasculitides.[31] Furthermore, some authors have
explored other, potentially more speciﬁc, radiolabelled tracers
(e.g., [11C]-PK11195), and other imaging modalities (e.g., PET/
MRI), which may be superior for locating or ruling out the
particular comorbidities in AAV patients. However, these
subjects have only been sporadically assessed in the literature
and were outside the scope of this study
In conclusion, FDG-PET/CT is a promising modality for ruling
out focal infection or malignancy in AAV patients with
nonspeciﬁc symptoms and a need for differentiating suspected
disease relapse from malignancy or infection. These comorbid-
ities were correctly ruled out in all but case involving the urinary
tract wherein the limited value of FDG-PET/CT is already well
established. The ultimate implication of this study is that FDG-
PET/CT may be suitable for use in the differential diagnosis in all
similarly situated AAV patients. However, owing to the size and
nature of the patient cohort, to establish the external validity
more ﬁrmly, further research in a larger patient population in a
prospective setting is desirable to determine whether FDG PET/
CT should be applied to all AAV patients suspected of
malignancy or infection indistinguishable from disease relapse.
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